Search Results
Aug 26, 2026, 02:36 ET Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Korea, Aug. 26, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and SK Biopharmaceuticals Co., Ltd. ("SK Biopharmaceuticals") today announced a strategic global licensing and collaboration agreement under which SK
More news about: Biohaven Ltd.
Aug 25, 2026, 16:41 ET Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University ("Yale") today announced that the U.S. District Court for the District of Delaware has entered judgment in their favor in the trade
More news about: Biohaven Ltd.
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
advance.NEW HAVEN, Conn., August 10, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing
More news about: Biohaven Ltd.
Aug 06, 2026, 07:00 ET Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
developmentNEW HAVEN, Conn., Aug. 6, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global biopharmaceutical company, today announced the appointment of John Yetimoglu to its Board of Directors, effective immediately.
More news about: Biohaven Ltd.
Jul 27, 2026, 07:00 ET Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University ("Yale") today announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their
More news about: Biohaven Ltd.
Jul 20, 2026, 07:30 ET Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
blockade.NEW HAVEN, Conn., July 20, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies
More news about: Biohaven Ltd.
Jul 09, 2026, 17:00 ET Biohaven Announces Scientific Leadership Transitions
officerNEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations.
More news about: Biohaven Ltd.
Jun 30, 2026, 07:30 ET Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
opakalimNEW HAVEN, Conn., June 30, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat
More news about: Biohaven Ltd.
Jun 29, 2026, 07:30 ET Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
disease.NEW HAVEN, Conn., June 29, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300 is the first MoDE extracellular
More news about: Biohaven Ltd.
Jun 01, 2026, 07:30 ET Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
immunology NEW HAVEN, Conn., June 1, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies
More news about: Biohaven Ltd.
May 27, 2026, 07:30 ET Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
BHV-1400.NEW HAVEN, Conn., May 27, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies
More news about: Biohaven Ltd.
May 26, 2026, 07:30 ET Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
registration.NEW HAVEN, Conn., May 26, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a
More news about: Biohaven Ltd.
May 04, 2026, 16:02 ET Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
inhibition.NEW HAVEN, Conn., May 4, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing
More news about: Biohaven Ltd.
Mar 19, 2026, 07:30 ET Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
NEW HAVEN, Conn., March 19, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing
More news about: Biohaven Ltd.
Mar 02, 2026, 16:05 ET Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
program.NEW HAVEN, Conn., March 2, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing
More news about: Biohaven Ltd.
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
aging.NEW HAVEN, Conn., Jan. 12, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies
More news about: Biohaven Ltd.
Jan 07, 2026, 07:00 ET Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
NEW HAVEN, Conn., Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at The
More news about: Biohaven Ltd.
Dec 24, 2025, 13:00 ET Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies
More news about: Biohaven Ltd.
Dec 11, 2025, 07:00 ET Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
LONDON and NEW HAVEN, Conn., Dec. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology
More news about: Biohaven Ltd.
Nov 13, 2025, 16:05 ET Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
NEW HAVEN, Conn., Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a
More news about: Biohaven Ltd.
Nov 12, 2025, 07:15 ET Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
NEW HAVEN, Conn., Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a
More news about: Biohaven Ltd.
Nov 11, 2025, 16:05 ET Biohaven Announces Proposed Public Offering of Common Shares
NEW HAVEN, Conn., Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a
More news about: Biohaven Ltd.
Nov 10, 2025, 06:58 ET Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
NEW HAVEN, Conn., Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing
More news about: Biohaven Ltd.
Nov 04, 2025, 20:06 ET FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
NEW HAVEN, Conn., Nov. 4, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies
More news about: Biohaven Ltd.
Sep 12, 2025, 08:45 ET Biohaven Ltd. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN
12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP